Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYR NASDAQ:BFRI NASDAQ:GNTA NASDAQ:MGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$0.47-8.4%$0.71$0.40▼$7.29$50.30M0.554.62 million shs2.78 million shsBFRIBiofrontera$0.94-6.0%$0.98$0.55▼$1.19$12.74M0.83258,960 shs205,278 shsGNTAGenenta Science$2.04+4.1%$0.82$0.55▼$10.00$46.24M0.94.16 million shs729,555 shsMGXMetagenomi$1.28-3.8%$1.38$1.24▼$3.95$50.07M0.64187,178 shs274,563 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma+2.58%+5.25%-39.09%-37.74%-90.02%BFRIBiofrontera+0.96%+15.70%-13.48%+15.83%+57.99%GNTAGenenta Science-7.11%+118.99%+192.54%+127.88%-55.05%MGXMetagenomi0.00%-5.00%-5.67%-10.14%-21.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$0.47-8.4%$0.71$0.40▼$7.29$50.30M0.554.62 million shs2.78 million shsBFRIBiofrontera$0.94-6.0%$0.98$0.55▼$1.19$12.74M0.83258,960 shs205,278 shsGNTAGenenta Science$2.04+4.1%$0.82$0.55▼$10.00$46.24M0.94.16 million shs729,555 shsMGXMetagenomi$1.28-3.8%$1.38$1.24▼$3.95$50.07M0.64187,178 shs274,563 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma+2.58%+5.25%-39.09%-37.74%-90.02%BFRIBiofrontera+0.96%+15.70%-13.48%+15.83%+57.99%GNTAGenenta Science-7.11%+118.99%+192.54%+127.88%-55.05%MGXMetagenomi0.00%-5.00%-5.67%-10.14%-21.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRaTyr Pharma 2.25Hold$21.004,368.09% UpsideBFRIBiofrontera 2.00HoldN/AN/AGNTAGenenta Science 1.00SellN/AN/AMGXMetagenomi 2.80Moderate Buy$9.00603.13% UpsideCurrent Analyst Ratings BreakdownLatest BFRI, MGX, GNTA, and ATYR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026ATYRaTyr Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/20/2026ATYRaTyr Pharma Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/19/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026MGXMetagenomi Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$12.00 ➝ $9.005/1/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)3/27/2026GNTAGenenta Science Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/6/2026ATYRaTyr Pharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRaTyr Pharma$190K242.54N/AN/A$0.69 per share0.68BFRIBiofrontera$41.71M0.29N/AN/A$0.90 per share1.04GNTAGenenta ScienceN/AN/AN/AN/A$1.29 per shareN/AMGXMetagenomi$25.21M1.91N/AN/A$4.22 per share0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRaTyr Pharma-$74.12M-$0.73N/AN/AN/AN/A-100.14%-73.55%8/6/2026 (Estimated)BFRIBiofrontera-$10.54M-$0.97N/A15.58N/A-25.66%-515.34%-53.91%8/12/2026 (Estimated)GNTAGenenta Science-$7.39MN/AN/AN/AN/AN/AN/AN/AN/AMGXMetagenomi-$87.87M-$2.30N/AN/AN/A-384.61%-51.23%-36.62%8/11/2026 (Estimated)Latest BFRI, MGX, GNTA, and ATYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ATYRaTyr Pharma-$0.16-$0.11+$0.05-$0.11N/AN/A5/14/2026Q1 2026BFRIBiofrontera-$0.1150-$0.41-$0.2950-$0.41$10.25 million$10.08 million5/11/2026Q1 2026MGXMetagenomi-$0.60-$0.61-$0.01-$0.61$5.90 million$1.25 million3/31/2026Q4 2025GNTAGenenta Science-$0.3641-$0.0750+$0.2891-$0.0750N/AN/A3/19/2026Q4 2025BFRIBiofrontera$0.29$0.50+$0.21$0.47$16.15 million$17.10 million3/5/2026Q4 2025ATYRaTyr Pharma-$0.18-$0.14+$0.04-$0.14$0.02 millionN/A3/5/2026Q4 2025MGXMetagenomi-$0.58-$0.60-$0.02-$0.60$7.33 million$3.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATYRaTyr PharmaN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRaTyr PharmaN/A5.785.78BFRIBiofrontera0.781.201.09GNTAGenenta Science0.3514.1614.16MGXMetagenomiN/A6.436.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRaTyr Pharma61.72%BFRIBiofrontera10.08%GNTAGenenta Science15.13%MGXMetagenomiN/AInsider OwnershipCompanyInsider OwnershipATYRaTyr Pharma5.75%BFRIBiofrontera4.80%GNTAGenenta Science28.99%MGXMetagenomi12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRaTyr Pharma5398.05 million92.41 millionOptionableBFRIBiofrontera7012.80 million12.19 millionNo DataGNTAGenenta Science723.59 million16.75 millionNot OptionableMGXMetagenomi23637.65 million32.94 millionN/ABFRI, MGX, GNTA, and ATYR HeadlinesRecent News About These CompaniesDid Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?June 5 at 3:45 PM | prnewswire.comMetagenomi (NASDAQ:MGX) Stock Rating Upgraded by Wall Street ZenMay 30, 2026 | americanbankingnews.comMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comMetagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50May 14, 2026 | msn.comMetagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their EstimatesMay 14, 2026 | finance.yahoo.comMetagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsMay 12, 2026 | markets.businessinsider.comMetagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue EstimatesMay 11, 2026 | zacks.comMetagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 9, 2026 | marketbeat.comMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing ...April 16, 2026 | markets.businessinsider.comMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyApril 16, 2026 | globenewswire.comDid Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?April 13, 2026 | prnewswire.comMetagenomi Therapeutics: Q4 Earnings SnapshotMarch 5, 2026 | sfgate.comMetagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue EstimatesMarch 5, 2026 | zacks.comMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial ResultsMarch 5, 2026 | globenewswire.comMetagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference TranscriptMarch 4, 2026 | seekingalpha.comMetagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare ConferenceFebruary 23, 2026 | globenewswire.comMGX Resources Limited (MTGRY) Q2 2026 Earnings Call Prepared Remarks TranscriptFebruary 18, 2026 | seekingalpha.comIs Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?February 12, 2026 | finance.yahoo.comMGX Resources Limited (MTGRY) Shareholder/Analyst Call Prepared Remarks TranscriptJanuary 22, 2026 | seekingalpha.comMetagenomi, Inc.: Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate OutlookJanuary 12, 2026 | finanznachrichten.deMetagenomi Therapeutics Rebrands to Emphasize Therapeutic FocusJanuary 12, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Navitas: NVIDIA’s AI Power Broker?By Jeffrey Neal Johnson | June 5, 2026BFRI, MGX, GNTA, and ATYR Company DescriptionsaTyr Pharma NASDAQ:ATYR$0.47 -0.04 (-8.38%) Closing price 04:00 PM EasternExtended Trading$0.47 +0.00 (+0.43%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Biofrontera NASDAQ:BFRI$0.94 -0.06 (-6.03%) Closing price 04:00 PM EasternExtended Trading$0.96 +0.03 (+3.21%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Genenta Science NASDAQ:GNTA$2.04 +0.08 (+4.08%) Closing price 04:00 PM EasternExtended Trading$1.87 -0.17 (-8.33%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Metagenomi NASDAQ:MGX$1.28 -0.05 (-3.76%) Closing price 04:00 PM EasternExtended Trading$1.28 +0.00 (+0.39%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
